Breast Cancer Coverage from Every Angle

Erica L. Mayer, MD, PhD, on Clinical Considerations for New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy in Metastatic Breast Cancer

Posted: Saturday, December 10, 2022

Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses some of the treatment implications based on data from the PACE study of patients with patients with endocrine- and CDK4/6 inhibitor-pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on prior CDK4/6 inhibitor therapy did not improve progression-free survival compared with fulvestrant alone, but a longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. Dr. Mayer details adverse events of the emerging regimens.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.